PL2371385T3 - Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń - Google Patents

Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń

Info

Publication number: PL2371385T3
Authority: PL; Poland
Prior art keywords: pigs; reduction; immunogenic composition; clinical signs; signs
Prior art date: 2005-12-29

Application number

PL11164854T

Other languages

English (en)

Inventor

Michael B Roof

Marc Allan Eichmeyer

Greg Nitzel

Phillip Wayne Hayes

Merrill Lynn Schaeffer

Original Assignee

Boehringer Ingelheim Vetmedica Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-29

Filing date

2006-12-28

Publication date

2016-02-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38371964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2371385(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-12-28 Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc

2016-02-29 Publication of PL2371385T3 publication Critical patent/PL2371385T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10051—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10071—Demonstrated in vivo effect
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Virology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

PL11164854T 2005-12-29 2006-12-28 Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń PL2371385T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US75501605P	2005-12-29	2005-12-29
US82980906P	2006-10-17	2006-10-17
EP06850366.3A EP1976558B1 (en)	2005-12-29	2006-12-28	Pcv2 immunogenic composition for lessening clinical symptoms in pigs
EP11164854.9A EP2371385B1 (en)	2005-12-29	2006-12-28	Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs

Publications (1)

Publication Number	Publication Date
PL2371385T3 true PL2371385T3 (pl)	2016-02-29

Family

ID=38371964

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL11164849T PL2371382T3 (pl)	2005-12-29	2006-12-28	Zastosowanie kompozycji immunogennej PCV2 do zmniejszania objawów klinicznych u świń
PL11164850T PL2371383T3 (pl)	2005-12-29	2006-12-28	Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
PL11164854T PL2371385T3 (pl)	2005-12-29	2006-12-28	Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
PL16185663T PL3127551T3 (pl)	2005-12-29	2006-12-28	Kompozycja immunogenna pcv2 do zmniejszania objawów klinicznych u świń

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL11164849T PL2371382T3 (pl)	2005-12-29	2006-12-28	Zastosowanie kompozycji immunogennej PCV2 do zmniejszania objawów klinicznych u świń
PL11164850T PL2371383T3 (pl)	2005-12-29	2006-12-28	Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL16185663T PL3127551T3 (pl)	2005-12-29	2006-12-28	Kompozycja immunogenna pcv2 do zmniejszania objawów klinicznych u świń

Country Status (18)

Country	Link
US (12)	US20080181910A1 (pl)
EP (11)	EP2371384A1 (pl)
JP (2)	JP5739602B2 (pl)
KR (2)	KR20140019479A (pl)
CN (4)	CN104474541B (pl)
AR (1)	AR058871A1 (pl)
AU (1)	AU2006338182B2 (pl)
BR (1)	BRPI0620823B1 (pl)
CA (1)	CA2635430A1 (pl)
DK (5)	DK2371385T3 (pl)
ES (5)	ES2625903T3 (pl)
HU (4)	HUE026205T2 (pl)
MX (4)	MX2008008311A (pl)
PL (4)	PL2371382T3 (pl)
PT (3)	PT2371383E (pl)
SG (1)	SG170792A1 (pl)
TW (1)	TW200800256A (pl)
WO (1)	WO2007094893A2 (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2772047B1 (fr) *	1997-12-05	2004-04-09	Ct Nat D Etudes Veterinaires E	Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US7700285B1 (en)	2005-12-29	2010-04-20	Boehringer Ingelheim Vetmedica, Inc.	PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru)	2004-12-30	2011-08-25	Берингер Ингельхейм Ветмедика, Инк.	Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en)	2004-12-30	2010-11-16	Boehringer Ingelheim Vetmedica, Inc.	Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US8834891B2 (en)	2005-03-14	2014-09-16	Boehringer Ingelheim Vetmedica, Inc.	Immunogenic compositions comprising Lawsonia intracellularis
DK1968630T5 (en) *	2005-12-29	2018-08-13	Boehringer Ingelheim Vetmedica Inc	MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS.
SG170792A1 (en) *	2005-12-29	2011-05-30	Boehringer Ingelheim Vetmed	Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
EP2099927A4 (en) *	2006-11-22	2010-05-05	Boehringer Ingelheim Vetmed	Methods of reducing porcine circovirus-associated disease outbreaks
EP2101815A4 (en)	2006-12-11	2010-10-06	Boehringer Ingelheim Vetmed	Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
WO2008076915A2 (en) *	2006-12-15	2008-06-26	Boehringer Ingelheim Vetmedica, Inc.	Treatment of pigs with pcv2 antigen
EP1941903A1 (en) *	2007-01-03	2008-07-09	Boehringer Ingelheim Vetmedica Gmbh	Prophylaxis and treatment of PRDC
EP1958644A1 (en)	2007-02-13	2008-08-20	Boehringer Ingelheim Vetmedica Gmbh	Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) *	2007-09-04	2010-11-09	Boehringer Ingelheim Vetmedica, Inc.	Reduction of concomitant infections in pigs by the use of PCV2 antigen
WO2009085912A1 (en) *	2007-12-21	2009-07-09	Wyeth	Methods and compositions for immunizing pigs against porcine circovirus
CA2710558A1 (en) *	2007-12-31	2009-07-16	Boehringer Ingelheim Vetmedica, Inc.	Pcv2 orf2 virus like particle with foreign amino acid insertion
CN101980720A (zh) *	2008-01-23	2011-02-23	贝林格尔.英格海姆维特梅迪卡有限公司	Pcv2猪肺炎支原体致免疫组合物及其制备方法
US20110033495A1 (en) *	2008-02-15	2011-02-10	Boehringer Ingelheim Vetmedica, Inc.	Methods and compositions for reducing the impact of enteric diseases
TWI449533B (zh)	2008-04-18	2014-08-21	Intervet Int Bv	防備胞內勞森菌（Ｌａｗｓｏｎｉａｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅｃｉｒｃｏｖｉｒｕｓ）用疫苗
AR078253A1 (es)	2009-09-02	2011-10-26	Boehringer Ingelheim Vetmed	Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
MX352641B (es)	2010-07-08	2017-12-01	United Biomedical Inc	Vacuna contra pcv2 basada en peptidos de diseño.
TWI508974B (zh)	2010-12-22	2015-11-21	Sbc Virbac Ltd	豬第二型環狀病毒(Porcine Circovirus Type 2)、含彼之免疫組合物、檢測套組及其應用
UA114503C2 (uk)	2012-04-04	2017-06-26	Зоетіс Сервісіз Ллс	Комбінована вакцина pcv та mycoplasma hyopneumoniae
MX373669B (es)	2013-09-25	2020-04-02	Zoetis Services Llc	Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso.
CN105658660A (zh)	2013-10-02	2016-06-08	勃林格殷格翰动物保健公司	Pcv2 orf2蛋白变体和由其组成的病毒样颗粒
MX370584B (es)	2013-12-03	2019-12-17	Intervet Int Bv	Vacuna contra lawsonia intracellularis y circovirus porcino 2.
PL3076996T3 (pl)	2013-12-03	2020-05-18	Intervet International B.V.	Szczepionka przeciwko cirkowirusowi świń typu 2
US10450351B2 (en) *	2015-10-16	2019-10-22	Kansas State University Research Foundation	Porcine circovirus type 3 immunogenic compositions and methods of making and using the same
RU2701816C1 (ru) *	2015-12-28	2019-10-01	Эгрикалчурал Текнолоджи Рисерч Инститьют	Способ получения капсидного белка цирковируса свиней 2 типа и содержащая его фармацевтическая композиция
RU2018137036A (ru)	2016-03-23	2020-04-23	Интервет Интернэшнл Б.В.	Комбинированная вакцина против инфекции вирусами pcv2 и prrs, содержащая альбумин
EP3432919A1 (en)	2016-03-23	2019-01-30	Intervet International B.V.	A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection
US11654191B2 (en)	2016-03-23	2023-05-23	Intervet Inc.	Vaccine for intradermal application against PCV2 and PRRS virus infection
US11622872B2 (en)	2016-05-16	2023-04-11	Elixir Medical Corporation	Uncaging stent
CN109561955B (zh)	2016-05-16	2021-04-16	万能医药公司	撑开支架
WO2019033121A1 (en)	2017-08-11	2019-02-14	Elixir Medical Corporation	Uncaging stent
JP6941171B2 (ja)	2016-11-03	2021-09-29	ベーリンガーインゲルハイムフェトメディカゲーエムベーハーＢｏｅｈｒｉｎｇｅｒＩｎｇｅｌｈｅｉｍＶｅｔｍｅｄｉｃａＧｍｂＨ	ブタパルボウイルスおよびブタ繁殖呼吸障害症候群ウイルスに対するワクチン、ならびにこれらを作製する方法
CN110446502B (zh)	2017-04-13	2024-01-26	英特维特国际股份有限公司	用于联合非混合使用的含猪病原体的疫苗
CN109010818B (zh) *	2017-06-09	2021-11-09	普莱柯生物工程股份有限公司	一种预防和/或治疗猪圆环病毒感染的二联疫苗组合物及其制备方法和应用
HUE068390T2 (hu)	2017-08-03	2024-12-28	Intervet Int Bv	2b genotípusú PCV2 ORF2 proteint tartalmazó vakcina
KR102665710B1 (ko)	2017-08-24	2024-05-14	노보 노르디스크 에이/에스	Glp-1 조성물 및 그 용도
KR102905685B1 (ko)	2018-03-26	2025-12-30	베링거 인겔하임 애니멀 헬스 유에스에이 인크.	면역원성 조성물의 제조방법
CN114222579A (zh)	2019-04-04	2022-03-22	勃林格殷格翰动物保健美国有限公司	猪圆环病毒3型（pcv3）疫苗及其生产和用途
MX2022003090A (es)	2019-09-12	2022-04-11	Intervet Int Bv	Vacuna combinada para ser administrable intradermicamente.
JP7761567B2 (ja)	2020-02-18	2025-10-28	ノヴォノルディスクアー／エス	医薬製剤
FR3107454B1 (fr)	2020-02-20	2023-02-10	Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic	Adjuvant de vaccin comprenant un microlatex inverse
US20230338500A1 (en)	2020-04-20	2023-10-26	Intervet Inc.	A combination of vaccines to prophylactically treat a pig
CA3185751A1 (en)	2020-07-24	2022-01-27	Edgar DIAZ	Combination porcine vaccine
KR20230098240A (ko)	2020-10-29	2023-07-03	인터벳 인터내셔널 비.브이.	다양한 장애에 대해 돼지를 보호하기 위한 조합 백신

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US755016A (en)	1903-06-08	1904-03-22	Charles Herschel Koyl	Coal-separating apparatus.
US829809A (en)	1906-04-10	1906-08-28	Arthur H Swan	Peel-blade tip.
US2909462A (en)	1955-12-08	1959-10-20	Bristol Myers Co	Acrylic acid polymer laxative compositions
US3479705A (en)	1966-12-15	1969-11-25	Miami Brick & Stone Inc Of Mia	Molding apparatus
NL7903764A (nl)	1979-05-14	1980-11-18	Shell Int Research	Werkwijze ter bereiding van calcium-houdend lood, daarmee verkregen lood en daaruit verkregen accuplaten of -roosters.
CA1247080A (en)	1983-03-08	1988-12-20	Commonwealth Serum Laboratories Commission	Antigenically active amino acid sequences
ZA881694B (en)	1987-03-17	1988-09-06	Akzo N.V.	Adjuvant mixture
US5069901A (en)	1988-02-03	1991-12-03	Jones Elaine V	Preparation of a recombinant subunit vaccine against pseudorabies infection
AU638970B2 (en)	1989-01-23	1993-07-15	Auspharm International Limited	Vaccine composition
US5155037A (en)	1989-08-04	1992-10-13	The Texas A&M University System	Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5202430A (en) *	1990-01-16	1993-04-13	University Of Tennessee	Transmissible gastroenteritis virus genes
ES2112274T5 (es)	1990-05-29	2006-03-01	Wyeth Holdings Corporation	Vacuna contra la pneumonia en cerdos y metodo para la preparacion de la misma.
JP3046332B2 (ja) *	1990-08-02	2000-05-29	協和醗酵工業株式会社	発酵法によるアミノ酸の製造法
US5565205A (en) *	1990-08-16	1996-10-15	Solvay Animal Health, Inc.	Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
NL9301272A (nl)	1993-07-20	1995-02-16	Aesculaap Bv	Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus.
GB9023111D0 (en) *	1990-10-24	1990-12-05	Wellcome Found	Expression system
CA2094515C (en) *	1990-11-01	1998-09-01	Theodore T. Kramer	Bacterial attenuation method and vaccine
US6042830A (en)	1992-08-05	2000-03-28	Boehringer Ingelheim Vetmedica, Inc.	Viral agent associated with mystery swine disease
MX9204885A (es)	1991-08-26	1994-05-31	Boehringer Animal Health Inc	Composicion de vacuna que comprende virus del sindrome de infertilidad y respiratorio de los cerdos.
US5580557A (en)	1991-10-09	1996-12-03	Iowa State University Research Foundation, Inc.	Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals
US5338543A (en)	1992-02-27	1994-08-16	Ambico, Inc.	Thimerosal inactivated mycoplasma hyopneumoniae vaccine
CN1070078C (zh) *	1993-11-24	2001-08-29	中国农科院兰州兽医研究所	口蹄疫疫苗的生产工艺
NZ285324A (en)	1994-05-10	1998-08-26	American Home Prod	Vaccine containing modified live bovine respiratory syncytial virus (brsv) with an adjuvant and pharmaceutically acceptable carrier
US5885823A (en) *	1995-06-05	1999-03-23	Nobl Laboratories, Inc.	Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
US5888532A (en)	1996-08-16	1999-03-30	Pritsos; Chris A.	Treatment of alcoholism and related disorders with (nicotinamide-adenine dinucleotide) phosphate derivatives
ATE199022T1 (de) *	1996-10-09	2001-02-15	Akzo Nobel Nv	Europäische vakzinstämme des fortplanzungs- atmungs-syndromsvirus des sweins (prrsv)
US6391314B1 (en) *	1997-10-03	2002-05-21	Merial	Porcine circoviruses vaccines diagnostic reagents
US20060029617A1 (en)	1997-10-03	2006-02-09	Charreyre Catherine E	Porcine circovirus and Helicobacter combination vaccines and methods of use
US7192594B2 (en)	1997-10-03	2007-03-20	Merial Limited	Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
US6517843B1 (en)	1999-08-31	2003-02-11	Merial	Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US7211379B2 (en) *	1997-10-03	2007-05-01	Merial Sas	Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
UA78180C2 (uk)	1997-10-03	2007-03-15	Меріаль	Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
FR2781159B1 (fr)	1998-07-06	2000-10-06	Merial Sas	Vaccin circovirus et parvovirus porcin
AU2002302120B2 (en) *	1997-10-03	2006-01-19	Merial	Porcine circoviruses, vaccines and diagnostic reagents
US20040062775A1 (en) *	1997-12-05	2004-04-01	Agence Francaise De Securite Sanitaire Des Aliments	Circovirus sequences associated with piglet weight loss disease (PWD)
FR2772047B1 (fr)	1997-12-05	2004-04-09	Ct Nat D Etudes Veterinaires E	Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
CA2313806A1 (en)	1997-12-11	1999-06-17	University Of Saskatchewan	Postweaning multisystemic wasting syndrome virus from pigs
US6287856B1 (en)	1998-03-13	2001-09-11	University Of Georgia Research Foundation, Inc.	Vaccines against circovirus infections
US6294176B1 (en)	1998-07-10	2001-09-25	Schering-Plough Veterinary Corp.	Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
DE19836659A1 (de)	1998-08-13	2000-02-17	Hoechst Schering Agrevo Gmbh	Herbizide Mittel für tolerante oder resistente Baumwollkulturen
EP1050584B1 (en)	1998-11-19	2006-10-18	Azwell Inc.	Recombinant lysophosphatidic acid phosphatase
FR2789695B1 (fr) *	1999-02-11	2003-03-07	Merial Sas	Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
US6497883B1 (en) *	1999-06-10	2002-12-24	Merial	Porcine circovirus recombinant poxvirus vaccine
US6943152B1 (en)	1999-06-10	2005-09-13	Merial	DNA vaccine-PCV
GB9921146D0 (en)	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
WO2001017556A1 (fr)	1999-09-07	2001-03-15	Shionogi & Co., Ltd.	Préparations vaccinales administrables par les muqueuses
GB9921147D0 (en)	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
US6656478B1 (en)	1999-11-12	2003-12-02	Samuel D. Charles	Cross-protective salmonella vaccines
PT1248646E (pt)	1999-12-21	2008-03-19	Merial Sas	Composições e vacinas contendo antigénio(s) de cryptosporidium parvum e de outro patógeno entérico
US6808900B2 (en) *	2000-06-15	2004-10-26	Manitoba, University Of	Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
JP2004503234A (ja)	2000-06-15	2004-02-05	パーデュー・リサーチ・ファウンデーション	ブタの先天性振せん用ワクチン
US7018638B2 (en) *	2000-12-19	2006-03-28	Wyeth	Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en)	2000-12-19	2007-04-30	Wyeth Corp	Improved mycoplasma hyopneumoniae bacterin vaccine
JP2002247979A (ja)	2001-02-23	2002-09-03	Nippon Biologicals Inc	マレック病ワクチンおよびその製造方法
CZ304525B6 (cs) *	2001-03-27	2014-06-18	University Of Saskatchewan	Způsob kultivace circoviru
US20030096377A1 (en) *	2001-06-28	2003-05-22	Virginia Tech Intellectual Properties, Inc.	Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2
PT1474067E (pt) *	2001-07-02	2008-11-14	Pfizer Prod Inc	Vacinação numa dose com mycoplasma hyopneumoniae
US7361352B2 (en) *	2001-08-15	2008-04-22	Acambis, Inc.	Influenza immunogen and vaccine
US7276353B2 (en)	2001-12-12	2007-10-02	Virginia Tech Intellectual Properties, Inc.	Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en)	2001-12-12	2007-10-09	Virginia Tech Intellectual Properties, Inc.	Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US6841364B2 (en) *	2002-01-22	2005-01-11	Protatek International, Inc.	Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
US20040063188A1 (en)	2002-02-14	2004-04-01	Novavax, Inc.	Kit for treating gastrointestinal tract
WO2003077860A2 (en)	2002-03-13	2003-09-25	Biophysica, Inc.	BOSWELLIN COMPOSITIONS ENHANCED WITH 3-β-ACETYL-11-KETO-β-BOSWELLIC ACID (“AKBA”), INDUSTRIAL MANUFACTURE AND THEIR USES
US20030215455A1 (en) *	2002-05-14	2003-11-20	Bailey Reynolds	Vaccine stabilizer and method of use
US7194472B2 (en) *	2002-07-05	2007-03-20	Sun Microsystems Inc.	Extending role scope in a directory server system
US7335362B2 (en)	2002-07-19	2008-02-26	Beth Israel Deaconess Medical Center	Methods of treating pre-eclampsia or eclampsia
US7223207B1 (en) *	2002-09-13	2007-05-29	Simon Basyuk	Exercise and massage device
AU2002951692A0 (en)	2002-09-23	2002-10-17	Vital Biotech (Hong Kong) Limited	Improvements in or relating to vaccines
EP1599164B1 (en)	2003-02-03	2015-04-08	Cerebus Biologicals, Inc.	Methods for treating, preventing and detecting helicobacter infection
US7563449B2 (en)	2003-04-21	2009-07-21	Pfizer Inc,	Methods for reducing cattle reproductive diseases
CN1458167A (zh)	2003-06-02	2003-11-26	中国农业科学院哈尔滨兽医研究所	截短表达的猪圆环病毒ⅱ型衣壳蛋白抗原及其应用
US7335361B2 (en) *	2003-06-09	2008-02-26	Animal Technology Institute Taiwan	Fusion antigen used as vaccine
NO321276B1 (no)	2003-07-07	2006-04-18	Elkem Materials	Fremgangsmate for fremstilling av triklorsilan og silisium for bruk ved fremstilling av triklorsilan
AU2004259034C1 (en)	2003-07-24	2010-12-16	Boehringer Ingelheim Animal Health USA Inc.	Vaccine formulations comprising an oil-in-water emulsion
US7312065B2 (en) *	2003-07-25	2007-12-25	Boehringer Ingelheim Vetmedica, Inc.	Lawsonia intracellularis of European origin and vaccines, diagnostic agents and methods of use thereof
FR2861731B1 (fr) *	2003-10-30	2006-02-24	Centre Nat Rech Scient	Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
WO2005112995A1 (en)	2004-04-26	2005-12-01	Choongang Vaccine Laboratory Co., Ltd.	Inactivated mixed vaccine for porcine respiratory disease and the method of manufacturing thereof
CN1579553A (zh) *	2004-05-18	2005-02-16	浙江大学	Ii型猪圆环病毒核酸疫苗的制备方法及其应用
KR100478845B1 (ko)	2004-06-22	2005-03-24	채찬희	돼지 이유자돈 전신성 소모성 증후군 예방 및 치료용 생물학적 조성물
AU2005319716A1 (en)	2004-06-30	2006-06-29	Id Biomedical Corporation Of Quebec	Vaccine compositions for treating coronavirus infection
US7258075B1 (en) *	2004-08-13	2007-08-21	World Factory, Inc.	Collapsible bird feeder
UA95602C2 (ru)	2004-12-30	2011-08-25	Берингер Ингельхейм Ветмедика, Инк.	Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) *	2005-12-29	2010-04-20	Boehringer Ingelheim Vetmedica, Inc.	PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) *	2004-12-30	2010-11-16	Boehringer Ingelheim Vetmedica, Inc.	Methods of overexpression and recovery of porcine circovirus type 2 ORF2
KR20070096019A (ko) *	2005-01-13	2007-10-01	베링거잉겔하임베트메디카게엠베하	향상된 ｐｒｒｓ 백신
US7300785B2 (en)	2005-02-03	2007-11-27	Universiteit Ghent	Culturing circular ssDNA viruses for the production of vaccines
US8834891B2 (en)	2005-03-14	2014-09-16	Boehringer Ingelheim Vetmedica, Inc.	Immunogenic compositions comprising Lawsonia intracellularis
WO2006113435A2 (en)	2005-04-13	2006-10-26	Merial Limited	Method for porcine circovirus production and assays for monitoring production
US7691368B2 (en)	2005-04-15	2010-04-06	Merial Limited	Vaccine formulations
BRPI0615862A2 (pt)	2005-09-09	2011-05-31	Intervet Int Bv	vacina contra pcv-2, e, método para a manufatura de uma vacina
SG170792A1 (en) *	2005-12-29	2011-05-30	Boehringer Ingelheim Vetmed	Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
DK1968630T5 (en)	2005-12-29	2018-08-13	Boehringer Ingelheim Vetmedica Inc	MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS.
WO2007094983A2 (en)	2006-02-03	2007-08-23	Tanox, Inc.	Methods and compositions for the inhibition of hiv infection of t cells
EP2099927A4 (en)	2006-11-22	2010-05-05	Boehringer Ingelheim Vetmed	Methods of reducing porcine circovirus-associated disease outbreaks
EP2101815A4 (en)	2006-12-11	2010-10-06	Boehringer Ingelheim Vetmed	Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
WO2008076915A2 (en)	2006-12-15	2008-06-26	Boehringer Ingelheim Vetmedica, Inc.	Treatment of pigs with pcv2 antigen
EP1941903A1 (en)	2007-01-03	2008-07-09	Boehringer Ingelheim Vetmedica Gmbh	Prophylaxis and treatment of PRDC
EP1958644A1 (en)	2007-02-13	2008-08-20	Boehringer Ingelheim Vetmedica Gmbh	Prevention and treatment of sub-clinical pcvd
GB0712160D0 (en)	2007-06-22	2007-08-01	Univ Ghent	Methods and compositions in the treatment of procine circoviral infection
US20090017064A1 (en) *	2007-07-10	2009-01-15	Wyeth	Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en)	2007-09-04	2010-11-09	Boehringer Ingelheim Vetmedica, Inc.	Reduction of concomitant infections in pigs by the use of PCV2 antigen
CN101980720A (zh)	2008-01-23	2011-02-23	贝林格尔.英格海姆维特梅迪卡有限公司	Pcv2猪肺炎支原体致免疫组合物及其制备方法
US20110033495A1 (en)	2008-02-15	2011-02-10	Boehringer Ingelheim Vetmedica, Inc.	Methods and compositions for reducing the impact of enteric diseases
US8444989B1 (en)	2008-04-18	2013-05-21	Boehringer Ingelheim Vetmedica Gmbh	One dose vaccination against mycoplasma infections of pigs
US20100150959A1 (en)	2008-12-15	2010-06-17	Vectogen Pty Ltd.	PCV 2-Based Methods and Compositions for the Treatment of Pigs
AR078253A1 (es)	2009-09-02	2011-10-26	Boehringer Ingelheim Vetmed	Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
WO2011075379A1 (en)	2009-12-18	2011-06-23	Boehringer Ingelheim Vetmedica, Inc.	Multivalent vaccine against porcine teschovirus and other disease causing organisms in swine
EP2547770B1 (en)	2010-03-16	2019-11-27	Virginia Tech Intellectual Properties, Inc.	Live attenuated chimeric porcine circovirus vaccine
WO2012033911A2 (en)	2010-09-08	2012-03-15	The Johns Hopkins University	Polyionic papilloma virus-like particle (vlp) vaccines
CN103122352B (zh)	2012-09-27	2015-02-11	华中农业大学	一种猪圆环病毒2型重组杆状病毒及制备方法和应用
EP3587439A3 (en)	2013-03-01	2020-03-11	Boehringer Ingelheim Animal Health USA Inc.	Improved quantification of vaccine compositions
WO2014179200A1 (en)	2013-04-30	2014-11-06	Boehringer Ingelheim Vetmedica, Inc.	Orf2 protein of pcv2 subtype a (pcv2a) for use in cross-protection
WO2014187822A1 (en)	2013-05-22	2014-11-27	Boehringer Ingelheim Espana, S.A.	Method for the reduction of pcv-2 in a herd of swine
WO2015026912A1 (en)	2013-08-23	2015-02-26	Boehringer Ingelheim Vetmedica, Inc.	Porcine circovirus type 2 (pcv2) subunit vaccine
CN105658660A (zh)	2013-10-02	2016-06-08	勃林格殷格翰动物保健公司	Pcv2 orf2蛋白变体和由其组成的病毒样颗粒
EP3139979B1 (en)	2014-05-07	2023-07-05	Boehringer Ingelheim International GmbH	Unit, nebulizer and method
EP3277315A2 (en)	2015-03-30	2018-02-07	Boehringer Ingelheim Vetmedica, Inc.	Pcv2 orf2 carrier platform

2006
- 2006-12-28 SG SG201102211-8A patent/SG170792A1/en unknown
- 2006-12-28 WO PCT/US2006/062662 patent/WO2007094893A2/en not_active Ceased
- 2006-12-28 MX MX2008008311A patent/MX2008008311A/es active IP Right Grant
- 2006-12-28 CA CA002635430A patent/CA2635430A1/en not_active Abandoned
- 2006-12-28 EP EP11164852A patent/EP2371384A1/en not_active Withdrawn
- 2006-12-28 DK DK11164854.9T patent/DK2371385T3/en active
- 2006-12-28 ES ES06850366.3T patent/ES2625903T3/es active Active
- 2006-12-28 KR KR1020147001544A patent/KR20140019479A/ko not_active Ceased
- 2006-12-28 ES ES11164849.9T patent/ES2572736T3/es active Active
- 2006-12-28 EP EP20184598.9A patent/EP3766518B1/en active Active
- 2006-12-28 CN CN201410534901.9A patent/CN104474541B/zh active Active
- 2006-12-28 EP EP11164858A patent/EP2371386A1/en not_active Withdrawn
- 2006-12-28 PL PL11164849T patent/PL2371382T3/pl unknown
- 2006-12-28 US US11/617,435 patent/US20080181910A1/en not_active Abandoned
- 2006-12-28 HU HUE11164850A patent/HUE026205T2/en unknown
- 2006-12-28 AU AU2006338182A patent/AU2006338182B2/en active Active
- 2006-12-28 CN CN201811123454.2A patent/CN109125721A/zh active Pending
- 2006-12-28 AR ARP060105837A patent/AR058871A1/es not_active Application Discontinuation
- 2006-12-28 ES ES16185663T patent/ES2824113T3/es active Active
- 2006-12-28 ES ES11164854.9T patent/ES2553254T3/es active Active
- 2006-12-28 KR KR1020087018597A patent/KR20080093112A/ko not_active Ceased
- 2006-12-28 ES ES11164850.7T patent/ES2553253T3/es active Active
- 2006-12-28 HU HUE11164849A patent/HUE029552T2/en unknown
- 2006-12-28 EP EP10174456A patent/EP2275130A3/en not_active Withdrawn
- 2006-12-28 PT PT111648507T patent/PT2371383E/pt unknown
- 2006-12-28 DK DK11164849.9T patent/DK2371382T3/en active
- 2006-12-28 HU HUE16185663A patent/HUE051784T2/hu unknown
- 2006-12-28 MX MX2012007937A patent/MX343001B/es unknown
- 2006-12-28 EP EP11164854.9A patent/EP2371385B1/en not_active Revoked
- 2006-12-28 CN CN201410534903.8A patent/CN104383526B/zh active Active
- 2006-12-28 HU HUE11164854A patent/HUE025994T2/en unknown
- 2006-12-28 EP EP11164855A patent/EP2374475A1/en not_active Withdrawn
- 2006-12-28 DK DK16185663.8T patent/DK3127551T3/da active
- 2006-12-28 PL PL11164850T patent/PL2371383T3/pl unknown
- 2006-12-28 DK DK06850366.3T patent/DK1976558T3/en active
- 2006-12-28 CN CN200680053578.7A patent/CN101426522B/zh active Active
- 2006-12-28 EP EP11164856A patent/EP2374476A1/en not_active Withdrawn
- 2006-12-28 BR BRPI0620823A patent/BRPI0620823B1/pt active IP Right Grant
- 2006-12-28 EP EP06850366.3A patent/EP1976558B1/en not_active Revoked
- 2006-12-28 DK DK11164850.7T patent/DK2371383T3/en active
- 2006-12-28 EP EP11164849.9A patent/EP2371382B1/en not_active Revoked
- 2006-12-28 EP EP16185663.8A patent/EP3127551B1/en active Active
- 2006-12-28 EP EP11164850.7A patent/EP2371383B1/en not_active Revoked
- 2006-12-28 PL PL11164854T patent/PL2371385T3/pl unknown
- 2006-12-28 MX MX2013012700A patent/MX338626B/es unknown
- 2006-12-28 JP JP2008548847A patent/JP5739602B2/ja active Active
- 2006-12-28 PT PT111648549T patent/PT2371385E/pt unknown
- 2006-12-28 PT PT161856638T patent/PT3127551T/pt unknown
- 2006-12-28 TW TW095149552A patent/TW200800256A/zh unknown
- 2006-12-28 MX MX2016013804A patent/MX356667B/es unknown
- 2006-12-28 PL PL16185663T patent/PL3127551T3/pl unknown
2008
- 2008-06-11 US US12/136,923 patent/US7968285B2/en active Active
- 2008-06-11 US US12/137,105 patent/US20080279889A1/en not_active Abandoned
- 2008-06-11 US US12/137,067 patent/US7838214B2/en active Active
- 2008-06-11 US US12/136,942 patent/US7838213B2/en active Active
- 2008-06-11 US US12/137,086 patent/US20080267995A1/en not_active Abandoned
- 2008-06-11 US US12/137,141 patent/US7829273B2/en active Active
2011
- 2011-05-12 US US13/106,606 patent/US9011868B2/en active Active
2013
- 2013-01-04 JP JP2013000182A patent/JP2013067655A/ja active Pending
2015
- 2015-03-18 US US14/661,969 patent/US9669087B2/en active Active
2016
- 2016-03-21 US US15/076,381 patent/US9987349B2/en active Active
- 2016-08-26 US US15/249,158 patent/US9610345B2/en active Active
2018
- 2018-04-19 US US15/957,663 patent/US10568955B2/en active Active

Also Published As

Publication number	Publication date
US20080279889A1 (en)	2008-11-13
EP1976558A4 (en)	2009-04-29
ES2553254T3 (es)	2015-12-07
US20080267995A1 (en)	2008-10-30
HUE026205T2 (en)	2016-05-30
EP2371385B1 (en)	2015-08-19
HUE025994T2 (en)	2016-05-30
US20080260779A1 (en)	2008-10-23
ES2553253T3 (es)	2015-12-07
PL2371383T3 (pl)	2016-01-29
JP2009522310A (ja)	2009-06-11
DK2371383T3 (en)	2015-11-30
MX343001B (es)	2016-10-21
US7838214B2 (en)	2010-11-23
EP2374476A1 (en)	2011-10-12
US9011868B2 (en)	2015-04-21
US7829273B2 (en)	2010-11-09
HUE051784T2 (hu)	2021-03-29
ES2572736T3 (es)	2016-06-02
US20160193320A1 (en)	2016-07-07
EP1976558A2 (en)	2008-10-08
ES2824113T3 (es)	2021-05-11
TW200800256A (en)	2008-01-01
US20170049875A1 (en)	2017-02-23
DK1976558T3 (en)	2017-06-19
AU2006338182B2 (en)	2013-08-22
EP2275130A2 (en)	2011-01-19
US7968285B2 (en)	2011-06-28
WO2007094893A9 (en)	2016-09-09
US9987349B2 (en)	2018-06-05
KR20080093112A (ko)	2008-10-20
US10568955B2 (en)	2020-02-25
US20080181910A1 (en)	2008-07-31
EP2275130A3 (en)	2011-03-23
EP3127551A1 (en)	2017-02-08
EP3766518A1 (en)	2021-01-20
PT3127551T (pt)	2020-10-09
ES2625903T3 (es)	2017-07-20
US7838213B2 (en)	2010-11-23
MX2008008311A (es)	2009-03-04
PL3127551T3 (pl)	2020-12-28
AR058871A1 (es)	2008-02-27
CN104474541A (zh)	2015-04-01
EP3766518B1 (en)	2026-01-28
AU2006338182A1 (en)	2007-08-23
CN109125721A (zh)	2019-01-04
US20080261887A1 (en)	2008-10-23
US20080279876A1 (en)	2008-11-13
DK2371382T3 (en)	2016-06-13
CN101426522A (zh)	2009-05-06
JP2013067655A (ja)	2013-04-18
PT2371385E (pt)	2015-11-27
EP2371383A1 (en)	2011-10-05
EP2371382B1 (en)	2016-03-02
DK2371385T3 (en)	2015-11-30
US9669087B2 (en)	2017-06-06
EP1976558B1 (en)	2017-03-15
EP2371385A1 (en)	2011-10-05
EP3127551B1 (en)	2020-07-29
CN104383526B (zh)	2018-09-18
US20180236057A1 (en)	2018-08-23
EP2371384A1 (en)	2011-10-05
PT2371383E (pt)	2015-11-24
US20110217327A1 (en)	2011-09-08
BRPI0620823B1 (pt)	2017-02-21
US20150190498A1 (en)	2015-07-09
EP2374475A1 (en)	2011-10-12
SG170792A1 (en)	2011-05-30
US9610345B2 (en)	2017-04-04
WO2007094893A3 (en)	2008-11-06
EP2371383B1 (en)	2015-08-19
EP2371386A1 (en)	2011-10-05
CN101426522B (zh)	2014-11-12
WO2007094893A2 (en)	2007-08-23
CN104383526A (zh)	2015-03-04
MX338626B (es)	2016-04-26
CA2635430A1 (en)	2007-08-23
HUE029552T2 (en)	2017-03-28
PL2371382T3 (pl)	2016-08-31
KR20140019479A (ko)	2014-02-14
MX356667B (es)	2018-06-08
DK3127551T3 (da)	2020-10-12
US20080279875A1 (en)	2008-11-13
CN104474541B (zh)	2019-08-23
JP5739602B2 (ja)	2015-06-24
EP2371382A1 (en)	2011-10-05
BRPI0620823A2 (pt)	2011-11-22

Publication	Publication Date	Title
PL2371385T3 (pl)	2016-02-29	Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
FR22C1008I2 (fr)	2024-01-19	Composition immunogène
CY2018013I1 (el)	2018-09-05	Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
BRPI0716354A2 (pt)	2013-09-17	"composiÇço e mÉtodo"
PT1506781E (pt)	2005-07-29	Composicao para tratamento vaginal
CY2019042I1 (el)	2020-05-29	Οφθαλμολογικες συνθεσεις και η χρηση τους
EP2153838A4 (en)	2012-09-26	ANTI-NOROVIRUS AGENT AND COMPOSITION THEREOF
EP2327750A4 (en)	2011-12-07	LIABILITY AND LIABILITY THEREWITH
EP1962961A4 (en)	2010-12-01	HALF-BODY: THERAPEUTIC AGENTS ACTIVATED BY DIMÉRIZATION
IL191759A (en)	2015-05-31	Ganaxolone formulations and methods for the making and use thereof
ATE549019T1 (de)	2012-03-15	1-ä(3-hydroxy-adamant-1-ylamino)-acetylü- pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung
BRPI0718688A2 (pt)	2013-12-24	Composições de baixa irritação e métodos para preparar as mesmas.
DK1827412T3 (da)	2014-02-10	Sammensætninger til anvendelse i kirurgi
PL2059223T3 (pl)	2013-03-29	Kompozycja do pielęgnacji skóry
IL190885A0 (en)	2008-11-03	Immunogenic compositions and methods of use
ZA200710858B (en)	2008-12-31	Diclofenac formulations and methods of use
DK1940467T3 (da)	2017-02-13	Lægemiddelsammensætning med langvarig frigivelse
EP2298365A4 (en)	2013-01-23	MEDICAL COMPOSITION AND MEDICAL KIT
DE602005008726D1 (de)	2008-09-18	Verwendet
SI1744756T1 (sl)	2008-10-31	Uporaba meloksikamskih formulacij v veterinarski medicini
EP1879449A4 (en)	2009-12-16	SKIN CARE COMPOSITIONS AND METHODS
EP1914273A4 (en)	2010-04-21	ETHER COMPOSITION AND SOLUTION COMPOSITION
EP1977800A4 (en)	2010-05-26	CARD TOY
FI20041057L (fi)	2006-02-05	Pelkistysainekoostumus
EP2101736A4 (en)	2012-09-19	HOMOGENEOUS PULP AND GEL PREPARATIONS